GSK Wins Japan Approval for Hibsago in Hepatitis B
LONDON, UK, Aug 24, 2026 GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
hepatitis B
Advertisement
Aligos Therapeutics Starts Phase 1 Study of ALG-170675
SOUTH SAN FRANCISCO, Calif., August 12, 2026 Aligos Therapeutics, Inc. announced that its partner Xiamen Amoytop Biotech Co., Ltd....
Brii Bio Reports Positive ENSURE HBV Cure Study Results
DURHAM, N.C. and BEIJING, China, May 27, 2026 Brii Biosciences Limited (Brii Bio) has presented new late-breaking clinical and...
Precision BioSciences Reveals Breakthrough HBV Data
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
FDA Grants Historic Approval to Gilead’s Hepcludex for HDV
Foster City, California, USA – May 21, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration...
Advertisements
GSK Bepirovirsen Wins FDA Priority Review Breakthrough Status
LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...
Aligos-Amoytop $445M HBV Licensing Deal Expands Access
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
Roche Launches 4-in-1 cobas MPX-E Blood Screening Test
BASEL, Switzerland, March 30, 2026 Roche has announced the launch of its cobas® MPX-E assay, a next-generation 4-in-1 multiplex...
GSK Bepirovirsen Wins EMA Review for Hepatitis B Drug
London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...
HOOKIPA Completes Sale of HBV and HIV Programs to Gilead Sciences
NEW YORK and VIENNA – October 31, 2025 — HOOKIPA Pharma Inc. (OTC: HOOK) announced the completion of the...
Advertisement
